Kancera AB (Sweden) Insiders
| KAN Stock | SEK 1.52 0.09 6.29% |
Kancera AB employs about 5 people. The company is managed by 6 executives with a total tenure of roughly 12 years, averaging almost 2.0 years of service per executive, having 0.83 employees per reported executive. Breaking down Kancera AB's management performance can provide insight into the firm performance.
| Thomas Olin Insider CEO Director |
| Martin Norin Insider Chief Officer |
Kancera |
Kancera AB Management Team Effectiveness
The company has return on total asset (ROA) of (0.2736) % which means that it has lost $0.2736 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4732) %, meaning that it generated substantial loss on money invested by shareholders. Kancera AB's management efficiency ratios could be used to measure how well Kancera AB manages its routine affairs as well as how well it operates its assets and liabilities.Kancera AB Workforce Comparison
Kancera AB is currently regarded as number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 48.0. Kancera AB retains roughly 5.0 in number of employees claiming about 10% of stocks in Biotechnology industry.
Kancera AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Kancera AB Price Series Summation is a cross summation of Kancera AB price series and its benchmark/peer.
Kancera AB Notable Stakeholders
A Kancera AB stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kancera AB often face trade-offs trying to please all of them. Kancera AB's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kancera AB's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Thomas Olin | CEO Director | Profile | |
| Martin Norin | Chief Officer | Profile | |
| Hans Richter | Chief Officer | Profile | |
| Peter Selin | Exec Devel | Profile | |
| Niclas Brynne | Head Devel | Profile | |
| Torbjrn Lundstrm | Chief Officer | Profile |
About Kancera AB Management Performance
The success or failure of an entity such as Kancera AB often depends on how effective the management is. Kancera AB management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kancera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kancera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kancera AB , a biotechnology company, engages in the development and sale of drug candidates to pharmaceutical companies in Sweden and internationally. The company was founded in 2010 and is based in Solna, Sweden. Kancera AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
The data published in Kancera AB's official financial statements usually reflect Kancera AB's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kancera AB. For example, before you start analyzing numbers published by Kancera accountants, it's critical to develop an understanding of what Kancera AB's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Kancera AB's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kancera AB's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kancera AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kancera AB. Please utilize our Beneish M Score to check the likelihood of Kancera AB's management manipulating its earnings.
Kancera AB Workforce Analysis
Traditionally, organizations such as Kancera AB use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kancera AB within its industry.Kancera AB Manpower Efficiency
Return on Kancera AB Manpower
| Revenue Per Employee | 340.8K | |
| Revenue Per Executive | 284K | |
| Net Loss Per Employee | 9.1M | |
| Net Loss Per Executive | 7.6M | |
| Working Capital Per Employee | 2.2M | |
| Working Capital Per Executive | 1.8M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kancera AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Kancera Stock analysis
When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |